Mutually Beneficial Strategic Partnerships
We believe that collaboration is a key driver and accelerator of innovation and value creation in the drug discovery industry. NGM seeks to establish partnerships with leading pharmaceutical and biotechnology companies with a shared commitment to advancing the development and commercialization of breakthrough medicines.
Our current collaboration:
In February 2015 we formed a comprehensive strategic collaboration with Merck for the discovery, development and commercialization of novel therapies across a range of therapeutic areas. As part of the collaboration, Merck secured an exclusive worldwide license to our NP201 program, comprising NGM386, NGM395 and other NP201 agonist compounds. In addition, the collaboration includes a broad, multi-year drug discovery and early development program that provides NGM with extensive funding as well as research autonomy. Merck has the right to take an exclusive worldwide license to NGM programs funded by the collaboration that complete a human proof-of-concept study. If Merck exercises its option, Merck will be responsible for the global development and commercialization of that program, with NGM having the right to participate in a worldwide cost and profit share arrangement of up to 50%. NGM also has the option to co-detail optioned products in the United States.
In June 2013, we entered into a collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, to discover, develop and commercialize novel therapeutics from NGM’s Enteroendocrine Cell (EEC) discovery program for the treatment of type 2 diabetes and obesity. MedImmune and NGM will jointly advance first-in-class peptide and antibody drug candidates based on the discovered EEC hormones. MedImmune will have the option to license these candidates, and will be responsible for the global development, manufacture and commercialization of compounds resulting from the collaboration.
In September 2011, we entered into a collaboration with JDRF to discover biologic targets that regulate beta-cell growth, and to translate these findings into new treatments for type 1 diabetes. The partnership was extended in August 2013.
Business Development Contact
Business Development Inquiries: email@example.com